此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation - Effects on Physical Function

2019年3月14日 更新者:Palle Toft

Substudy of Non-Seda Trial (NCT01967680): Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation - Effects on Physical Function. An Investigator-initiated, Randomised, Clinical, Parallel-group, Multinational, Superiority Trial

Critically ill, ventilator-treated patients rapidly loose much of their muscle mass and strength. This can attribute to prolonged admission, prolonged mechanical ventilation, increased mortality and might have a negative impact on the physical function, degree of independence and quality of life. The pathophysiological background for the loss of muscle mass as well as possible effective treatment is still not well established. In the NONSEDA-trial we randomise critically ill patients to non-sedation or sedation with a daily wake-up trial during mechanical ventilation in the intensive care unit (ICU). It has never been assessed whether non-sedation reduces the loss of muscle mass and strength.

Aim: To assess the effects of non-sedation versus sedation with a daily wake-up trial on physical function after discharge from ICU.

Hypothesis: that non-sedation during ventilator-treatment will improve the physical function after ICU-discharge, compared with standard treatment of sedation with a daily wake-up.

研究概览

研究类型

介入性

注册 (实际的)

205

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Kolding、丹麦、6000
        • Lillebaelt Hospital, Kolding

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Endotracheally intubated
  • Expected time on ventilator > 24 hours
  • Age ≥ 18 years
  • Informed consent

Exclusion Criteria:

  • Severe head trauma where therapeutic coma is indicated
  • Therapeutic hypothermia where therapeutic coma is indicated
  • Status epilepticus where therapeutic coma is indicated
  • Patient has participated in the study before
  • Patient is transferred from another ICU with length of stay > 48 hours
  • Patient is comatose at admission
  • PaO2/FiO2 ≤ 9, if sedation is necessary for oxygenation

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Non-sedation

The experimental group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.

Participants will be awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium will be treated with haloperidol.

有源比较器:Sedation with daily wake-up

The control group will be sedated to Ramsay score 3-4. The first 48 hours the patients will be sedated with propofol, after 48 hours midazolam will be used. During daytime, the patient will be awakened as the intravenous infusion of sedatives will be discontinued. The patient will be considered to be awake when he/she can perform at least three of the following four tasks:

  • Open the eyes to verbal commands.
  • Follow the examiner's instructions with the eyes.
  • Squeeze hands on request.
  • Stick out the tongue on request.

After a successful wake-up, the infusion of sedative will be resumed, starting on half of the pre-wake-up dose and adjusted to Ramsey score 3-4.

其他名称:
  • Standard treatment, continuous iv-sedation

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Physical function
大体时间:3 months after ICU-discharge

Co-primary outcome of: patient-reported quality of life, as measured by SF-36v2, physical component and degree of independence in activities of daily living, as measured by Barthel Index.

Since this is a co-primary outcome, the type I error probability associated with the test of the null hypothesis should be less than 0,025.

3 months after ICU-discharge

次要结果测量

结果测量
措施说明
大体时间
6 minute walk
大体时间:3 months after ICU-discharge
Walking distance in the 6 minute walk test at 3 months follow-up
3 months after ICU-discharge
Handgrip
大体时间:3 months after ICU-discharge
Handgrip-strength at 3 month follow-up
3 months after ICU-discharge
Thigh muscle size
大体时间:3 months after ICU-discharge
Muscle size, measured as cross section area of the rectus femoris muscle at 3 months follow-up
3 months after ICU-discharge
Biomechanical data
大体时间:3 months after ICU-discharge
Muscle strength, measured using biomechanical measurements - Maximal voluntary contraction (MVC), rate of force developement (RFD) and endurance at 25% of MVC at 3 months follow-up
3 months after ICU-discharge

其他结果措施

结果测量
措施说明
大体时间
Biomechanical data
大体时间:Within 24 hours of ICU-discharge
Muscle strength - Maximal voluntary contraction (MVC), rate of force developement (RFD) and endurance at 25% of MVC at ICU-discharge.
Within 24 hours of ICU-discharge
Handgrip
大体时间:Within 24 hours of ICU-discharge
Handgrip-strength at ekstubation and at ICU-discharge.
Within 24 hours of ICU-discharge
Thigh muscle size
大体时间:Within 24 hours of ICU-discharge
Muscle size, measured as cross section area of the rectus femoris muscle at ekstubation and at ICU-discharge
Within 24 hours of ICU-discharge

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Helene K Nedergaard, MD、Lillebaelt Hospital, Kolding

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2014年1月1日

初级完成 (实际的)

2017年6月1日

研究完成 (实际的)

2019年3月1日

研究注册日期

首次提交

2014年1月9日

首先提交符合 QC 标准的

2014年1月10日

首次发布 (估计)

2014年1月14日

研究记录更新

最后更新发布 (实际的)

2019年3月15日

上次提交的符合 QC 标准的更新

2019年3月14日

最后验证

2019年3月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

肌肉萎缩的临床试验

  • GenSight Biologics
    不再可用
    Leber遗传性视神经病变(Optic, Atrophy, Hereditary, Leber)

Non-sedation的临床试验

3
订阅